
Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says
Vaxcyte's (PCVX) results for vaccine candidate VAX-24 came in below some Wall Street expectations bu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscripti...
- March 31, 2025 06:51 AM PDT
- EODHD

Two XPO Leaders Named 2025 Top Women to Watch in Transportation
GREENWICH, Conn., March 31, 2025 (GLOBE NEWSWIRE) -- XPO (NYSE: XPO), a leading provider of freight transportation in North America, announced today that senior director of engineering and the project...
- March 31, 2025 06:30 AM PDT
- EODHD

Sector Update: Energy Stocks Steady Premarket Monday
Energy stocks were steady premarket Monday with the Energy Select Sector SPDR Fund (XLE) recently in PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscripti...
- March 31, 2025 06:23 AM PDT
- EODHD

Progyny Expands Maternal Health Support with Addition of Doula Services
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Progyny (Nasdaq: PGNY), a global leader in women’s health and family building, is expanding its support throughout the maternal health journey with the add...
- March 31, 2025 06:22 AM PDT
- EODHD

Casey’s Marks 40 Years of Pizza with 40-Cent Slices
Casey’s Marks 40 Years of Pizza with 40-Cent Slices Guests invited to celebrate four decades of legendary pizza with delicious deals ANKENY, Iowa, March 31, 2025--(BUSINESS WIRE)--Casey’s (NASDAQ: CAS...
- March 31, 2025 06:00 AM PDT
- EODHD

Capcom’s Monster Hunter Wilds Tops 10 Million Units Sold!
Monster Hunter Wilds Title LogoMonster Hunter Wilds Main Visual - Sets company first-month sales record by combining the series’ appeal with new elements – OSAKA, Japan, March 31, 2025--(BUSINESS WIRE...
- March 31, 2025 06:00 AM PDT
- EODHD

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initi...
- March 31, 2025 06:00 AM PDT
- EODHD